medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 3

<< Back Next >>

Rev Invest Clin 2005; 57 (3)

The Impact of Losartan on the Lifetime Incidence of ESRD and Costs in Mexico

Arredondo A, Burke TA, Carides GW, Lemus E, Querol J

Language: Spanish
References: 16
Page: 399-405
PDF size: 61.52 Kb.


ABSTRACT

Background. The RENAAL (Reduction of Endpoints in Type 2 Diabetes with the Angiotensin II Antagonist Losartan) study demonstrated that treatment with losartan reduced the risk of ESRD by 29% among hypertensive patients with type 2 diabetes and diabetic nephropathy. The objective of this study was to project the effect of losartan compared to placebo on the lifetime incidence of ESRD and associated costs from a third-party payer perspective in Mexico. Methods. A competing risks method was used to estimate lifetime incidence of ESRD, while accounting for the risk of death without ESRD. The cost associated with ESRD was estimated by combining the cumulative incidence of ESRD with the lifetime cost associated with ESRD. Total cost was estimated as the sum of the cost associated with ESRD from the three main public institutions in Mexico, the lifetime cost of losartan therapy, and other costs (non-ESRD/non-losartan) expected for patients with type 2 diabetes. Survival was estimated by weighting the life expectancies with and without ESRD by the cumulative risk of ESRD. Results. The projected lifetime incidence of ESRD for losartan patients was lower (66%) compared with placebo patients (83%). This reduction in ESRD resulted in a decrease in ESRD-related cost of M$49,737 per patient and a discounted gain of 0.697 life years per patient. After accounting for the cost of losartan and the additional cost associated with greater survival, we projected that treatment with losartan would result in a net savings of M$24,073 per patient. Conclusion. Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the within-trial incidence of ESRD but is projected to result in lifetime reductions in ESRD, increased survival, and overall cost savings to public institutions in Mexico.


REFERENCES

  1. García PM, et al. Las múltiples facetas de la investigación en Salud. México, DF. IMSS; 2001, pp. 153-70.

  2. Keane H. Advances in slowing the progress of diabetic nephropathy. Patient Care 2001; 30: 28-41.

  3. Rodríguez Moctezuma. Características epidemiológicas de pacientes con diabetes-IRC en el Estado de México. Rev Med IMSS 2003; 41(5): 383-59.

  4. Brien H, Garcia H, Garcia G, et al. Epidemiología de la insuficiencia renal crónica en Jalisco. Boletín Colegio Jalisciense Nefrología 2001; 5: 6-8.

  5. Cueto-Manzano AM. Peritoneal dialysis in Mexico. Kidney International 2003; 63(Supl. 83): S90-S92.

  6. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.

  7. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease. Diabetes Care 2003; 26(3): 683-7.

  8. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.

  9. Lawless JF. Statistical Models and Methods for Lifetime Data. New York: Wiley, 1982.

  10. Akaike H. Information Theory and an extension of the maximum likelihood principle. In: 2nd International Symposium of Information Theory and Control. EBN Petrov and F Csaki (Eds.). Budapest: Akademia Kiado; 1973, pp. 267-81.

  11. Arredondo A. Costs for health care interventions in Mexican Health System. Mexico: National Institute of Public Health; 2004.

  12. Arredondo A. Financial requirements for health services demands for diabetes and hypertension in Mexico: 2001-2003. Rev Invest Clin 2001; 53(5): 422-9.

  13. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.

  14. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney International 2002; 62(Suppl. 82): S68-S72.

  15. Gerth WC, Ribeiro AB, Ferder LF, et al. Losartan reduces the burden of end-stage renal disease: Public Health Implications from the RENAAL Study for Latin America. Sociedad Iberoamericana de Información Científica (SIIC). In Press.

  16. UK National Institute for Clinical Excellence. Guide to the methods of technology appraisal. UK National Health Service; 2004.




2020     |     www.medigraphic.com